Stromal Vascular Fraction For Treatment Research Articles

Efficacy of stromal vascular fraction in the treatment of scars: A systematic review and meta-analysis.

Our aim was to assess the effectiveness of stromal vascular fraction (SVF) in treating scars using the latest meta-analysis. We used PubMed, Embase, Cochrane, and Web of Science to search the studies used to evaluate the efficacy of SVF in scar treatment. At least one of the following outcome measures were reported: vascularity, pigmentation, thickness, relief, pliability, surface area, pain, itching and color. A total of four eligible articles comprising 145 patients (64 SVF patients and 81 non-SVF patients) were included. The findings of this meta-analysis indicated that SVF had significant therapeutic effects in terms of vascularity (SMD/MD, 95% CI: -1.12, -0.02; p=0.04), itching (SMD/MD, 95% CI: -0.61, -0.13; p=0.002), POSAS (SMD/MD, 95% CI: -5.93, -1.47; p=0.001), and thickness (SMD/MD, 95% CI: -1.04, -0.35; p<0.001). In terms of OSAS (SMD/MD, 95% CI: -9.14, 0.59; p=0.09), pigmentation (SMD/MD, 95% CI: -1.02, 0.06; p=0.08), relief (SMD/MD, 95% CI: -1.14, 0.16; p=0.14), surface area (SMD/MD, 95% CI: -0.91, 0.26; p=0.27), PSAS (SMD/MD, 95% CI: -7.20, 0.49; p=0.09), pain (SMD/MD, 95% CI: -0.87, 0.07; p=0.10), pliability (SMD/MD, 95% CI: -0.57, 0.01; p=0.06), and color (SMD/MD, 95% CI: -1.78, 0.48; p=0.26), there were no significant statistical differences. In view of the heterogeneity and potential selective bias, further large-scale, prospective, and multicenter clinical trials are needed to confirm the efficacy and reliability of SVF in the treatment of scars.

Efficacy of adipose—derived stromal vascular fraction in treatment of osteoarthritis: an experimental study

BackgroundOsteoarthritis OA is a common progressive disabling disease. Current research aims at finding therapies to prevent its progression. In this work, we assessed the therapeutic role of intra-articular injection of stromal vascular fraction SVF in collagenase induced knee OA in rats.ResultsPost right Knee OA induction in 42 Wistar rats, histopathological examination and quantification of articular cartilage degeneration using Mankin’s score revealed degenerative changes were significantly higher in untreated Group II compared to SVF treated Group III at 1 month (10.75 ± 0.50 and 2.50 ± 0.53, P = 0.001) and 2 months (8.50 ± 0.58, 0.50 ± 0.53, P = 0.001), respectively. Morphometric computerized image analysis revealed a significant difference between treated, untreated and healthy control group I regarding chondrocyte cellular count, articular cartilage thickness and optical density OD of the cartilage (P < 0.001). Group II contained the least chondrocyte cellular count. Also, articular cartilage thickness at 2 months was significantly less in Group II compared to SVF treated group (P < 0.001). The OD in Safranin-stained slides, as an indicator of proteoglycan content of the matrix, was highest in Group I followed by Group III and lowest in Group II with a highly significant difference between untreated and treated groups at 1 month (67.32 ± 4.25, 81.77 ± 3.09, P = 0.000) and 2 months (71.60 ± 3.49, 83.26 ± 5.47, P = 0.000), respectively.ConclusionTreatment with adipose-derived SVF decreased the development of articular cartilage degenerative changes at early stages of induced OA in rats. Later, on follow-up, the preserved articular cartilage thickness, cellular count and increased proteoglycan content rendered SVF a promising regenerative therapy for Knee OA.

Clinicopathological studies on the use of laser-activated adipose-derived stromal vascular fraction in treatment of streptozotocin-induced diabetes in rats

Diabetes mellitus (DM) is associated with severe progressive degenerative complications in many organs especially diabetic nephropathy (DN). Adipose-derived stromal vascular fraction (SVF) is easily obtained and has abundant viable stem cell number obviating extensive expansion in culture; thus, SVF utilization provides promising anticipation. Low-intensity laser irradiation (LILI) was found to strengthen the therapeutic effect of non-expanded SVF through enhancing viability, protein expression, and migration of stem cells. The current study aimed to demonstrate the effect of transplanted laser-activated SVF in streptozotocin (STZ)-induced diabetic rats. Forty-five male Sprague Dawley rats were used in this experiment and divided randomly into four groups: (I) control group, (II) diabetic untreated group, (III) and (IV) diabetic-treated groups in which laser-activated SVF transplantation performed as a single and multiple IP injections, respectively, (V) cell tracking group. DM was induced by a single intraperitoneal (IP) injection of STZ at a dose of 55 mg/kg. Rats received single and multiple IP SVF injections, at a dose of 1.5 × 106 nucleated cells/rat on the 7th day of DM induction and a second dose injected in group IV on the 21th day of DM induction (2-week interval). Insulin gene expression quantification; glycemic profile evaluation (blood glucose, C-peptide, and glycosylated hemoglobin); biochemical, histopathological, and immunohistochemical parameters; and microalbuminuria were assessed in all experimental groups. Both SVF-treated groups exhibited improvement in glycemic profile which was confirmed by the significant increase of insulin gene expression and C-peptide levels. Liver transaminases, lipid profile, and microalbuminuria were normalized while serum creatinine and urea concentrations were ameliorated in treated groups compared to diabetic untreated rats. In conclusion, laser-activated SVF transplantation in diabetic rats triggered improvement of the diabetic state and ameliorated some of its complications with regard to the early interference. The second SVF treatment showed more improvement regarding the blood glucose, C-peptide, histopathology, and immunohistochemical results of the pancreas in diabetic states.

1220 - Autologous adipose tissue derived stromal vascular fraction for treatment of vasculogenic erectile dysfunction: Results of clinical trial phase I/II

1220 - Autologous adipose tissue derived stromal vascular fraction for treatment of vasculogenic erectile dysfunction: Results of clinical trial phase I/II

SAFETY AND EFFECTIVENESS OF INTRAARTICULAR ADMINISTRATION OF ADIPOSE-DERIVED STROMAL VASCULAR FRACTION FOR TREATMENT OF KNEE ARTICULAR CARTILAGE DEGENERATIVE DAMAGE: PRELIMINARY RESULTS OF A CLINICAL TRIAL

The incidence of knee osteoarthritis tends to increase every year and constitutes more than 83% of overall OA morbidity. Moreover, the OA morbidity among younger patients is also increasing. However, currently available treatment methods do not provide quite satisfactory outcomes.Purpose of the study – to evaluate safety and efficacy of intraarticular introduction of autologous adipose-derived stromal vascular fraction for treatment of knee osteoarthritis.Material and methods. By the moment of writing the present report, 28 patients were included into the study. All patients underwent tumescent liposuction under local anesthesia. The stromal vascular fraction was isolated from lipoaspirate within 1,5 hours after harvesting and subsequently injected into the articular cavity. Follow-up period was 6 months after injections. The authors report on efficacy data of 10 patients who completed the study according to protocol and safety data of all 28 patients. Efficacy was evaluated basing on laboratory assessments and patient’s subjective assessment by validated questionnaires.Results. Neither adverse reactions no adverse events were observed. Significant decrease of pain severity by VAS was noted in one week after injection and pain score continued decreasing during the whole follow up period. The increase of KOOS score was noted starting on the fifth week after injection. KSS part 1 score increased in 8 weeks, KSS part 2 score — in 6 months after injection. Physical health, assessed with SF-36 questionnaire significantly improved in 2 and 6 months after the procedure. There was a clear trend towards improvement of mental health.Conclusion. Preliminary results of clinical study suggest intraarticular injection of autologous adipose-derived stromal vascular fraction to be a safe and efficient method of the treatment of knee osteoarthritis.

Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety

Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapies have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach.

Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis

The stromal vascular fraction (SVF) of adipose tissue is known to contain mesenchymal stem cells (MSC), T regulatory cells, endothelial precursor cells, preadipocytes, as well as anti-inflammatory M2 macrophages. Safety of autologous adipose tissue implantation is supported by extensive use of this procedure in cosmetic surgery, as well as by ongoing studies using in vitro expanded adipose derived MSC. Equine and canine studies demonstrating anti-inflammatory and regenerative effects of non-expanded SVF cells have yielded promising results. Although non-expanded SVF cells have been used successfully in accelerating healing of Crohn's fistulas, to our knowledge clinical use of these cells for systemic immune modulation has not been reported. In this communication we discuss the rationale for use of autologous SVF in treatment of multiple sclerosis and describe our experiences with three patients. Based on this rationale and initial experiences, we propose controlled trials of autologous SVF in various inflammatory conditions.